29.08
+0(+0.00%)
Currency In USD
| Previous Close | 29.08 |
| Open | 28.78 |
| Day High | 29.08 |
| Day Low | 28.78 |
| 52-Week High | 30.39 |
| 52-Week Low | 5.21 |
| Volume | 624,025 |
| Average Volume | 135,968 |
| Market Cap | 145.36M |
| PE | -2.08 |
| EPS | -13.95 |
| Moving Average 50 Days | 22.88 |
| Moving Average 200 Days | 11.99 |
| Change | 0 |
Data not available
Day One Biopharmaceuticals to Acquire Mersana Therapeutics
GlobeNewswire Inc.
Nov 13, 2025 11:00 AM GMT
Agreement with Day One Biopharmaceuticals provides for upfront consideration of $25.00 per share in cash, plus potential contingent value rights cash payments of up to an aggregate of $30.25 per share, for aggregate deal value of up to approximately
Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025
GlobeNewswire Inc.
Nov 10, 2025 1:00 PM GMT
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical
Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025
GlobeNewswire Inc.
Aug 06, 2025 12:00 PM GMT
CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on the development of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical